Stay updated with breaking news from Interim Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that data from clinical and non-clinical studies of Endo Aesthetics' Qwo® (collagenase...
An experimental antiviral pill appears to work very well at keeping people who are at high risk of severe COVID-19 from being admitted to the hospital and dying, according to the drug's maker, Pfizer.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Several presentations will highlight broad potential of CD19-targeted ADC ZYNLONTA (loncastuximab tesirine-lpyl) as a single agent and in combination for the treatment of non-Hodgkin lymphomas ADC
KEYTRUDA Continued To Improve Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB or IIC Melanoma at 2 nd Interim Analysis of Phase 3 KEYNOTE-716 Trial Exploratory 7-Year Follow-Up Data for KEYTRUDA in Advanced Melanoma Showed 38% of Patients Treated With KEYTRUDA Were Alive at 7 Years Merck known as MSD outside the United States and Canada, today announced new data ...